Application of lipidomics to assess lipogenesis in drug development and pre-clinical trials

Current Pharmaceutical Biotechnology

Volumn 13, Issue 5, 2012, Pages 736-745

  Lamazière, Antonin ^a   Wolf, Claude ^a   Quinn, Peter J ^b  

^a SORBONNE UNIVERSITÉ   (France)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Diabesity; Lipidomics; Mass spectrometry; Metabolic syndrome; Multivariate analysis; Pharmacodynamics

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; DIHOMO GAMMA LINOLENIC ACID; FATTY ACID BINDING PROTEIN; GAMMA LINOLENIC ACID; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPIDOME; METFORMIN; PALMITIC ACID; PALMITOLEIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PROTEIN KINASE C; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; VERY LOW DENSITY LIPOPROTEIN;

ADIPOSE TISSUE; DRUG DEVELOPMENT; DRUG SCREENING; DYSLIPIDEMIA; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; IMMUNE RESPONSE; INFORMATION PROCESSING; LIPID COMPOSITION; LIPID METABOLISM; LIPID OXIDATION; LIPIDOMICS; LIPOGENESIS; LIPOLYSIS; MASS SPECTROMETER; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHARMACODYNAMICS; PROTEIN CLEAVAGE; REVIEW; WEIGHT REDUCTION;

ANIMALS; DRUG DISCOVERY; HUMANS; LIPID METABOLISM; LIPOGENESIS;

EID: 84860293737     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799857521     Document Type: Review

References (42)

1. Eckel, R. H.; Grundy, S. M.; Zimmet, P. Z. The metabolic syndrome. Lancet, 2005, 365, 1415-1428.
2. Cornier, M. A.; Dabelea, D.; Hernandez, T. L.; Lindstrom, R. C.; Steig, A. J.; Stob, N. R.; Van Pelt, R. E.; Wang, H.; Eckel, R. H. The metabolic syndrome. Endocr. Rev., 2008, 29, 777-822.
3. Tilg, H.; Hotamisligil, G. S. Nonalcoholic fatty liver disease: Cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology, 2006, 131, 934-945.
4. Stanhope, K. L.; Havel, P. J. Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. Am. J. Clin. Nutr., 2008, 88, 1733S-1737S.
5. Medina-Gomez, G.; Gray, S.; Vidal-Puig, A. Adipogenesis and lipotoxicity: role of peroxisome proliferator-activated receptor gamma (PPARgamma) and PPARgammacoactivator-1 (PGC1). Public Health Nutr., 2007, 10, 1132-1137.
6. Puglisi, M. J.; Fernandez, M. L. Modulation of C-reactive protein, tumor necrosis factor-alpha, and adiponectin by diet, exercise, and weight loss. J. Nutr., 2008, 138, 2293-2296.
7. Shoelson, S. E.; Herrero, L.; Naaz, A. Obesity, inflammation, and insulin resistance. Gastroenterology, 2007, 132, 2169-2180.
8. Gustafson, J. K.; Yanoff, L. B.; Easter, B. D.; Brady, S. M.; Keil, M. F.; Roberts, M. D.; Sebring, N. G.; Han, J. C.; Yanovski, S. Z.; Hubbard, V. S.; Yanovski, J. A. The stability of metabolic syndrome in children and adolescents. J. Clin. Endocrinol. Metab., 2009, 94, 4828-4834.
9. Leiter, E. H.; Reifsnyder, P. C.; Flurkey, K.; Partke, H. J.; Junger, E.; Herberg, L., NIDDM genes in mice: deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes, 1998, 47, 1287-1295.
10. Reifsnyder, P. C.; Churchill, G.; Leiter, E. H. Maternal environment and genotype interact to establish diabesity in mice. Genome Res., 2000, 10, 1568-1578.
11. Watkins, S. M.; Reifsnyder, P. R.; Pan, H. J.; German, J. B.; Leiter, E. H. Lipid metabolome-wide effects of the PPARgamma agonist rosiglitazone. J. Lipid Res., 2002, 43, 1809-1817.
12. Yki-Jarvinen, H., Thiazolidinediones and the liver in humans. Curr. Opin. Lipidol., 2009, 20, 477-483.
13. Knowler, W. C.; Fowler, S. E.; Hamman, R. F.; Christophi, C. A.; Hoffman, H. J.; Brenneman, A. T.; Brown-Friday, J. O.; Goldberg, R.; Venditti, E.; Nathan, D. M. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet, 2009, 374, 1677-1686.
14. Huang, P.; Chandra, V.; Rastinejad, F. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Annu. Rev. Physiol., 2010, 72, 247-272.
15. Zhao, L. F.; Iwasaki, Y.; Zhe, W.; Nishiyama, M.; Taguchi, T.; Tsugita, M.; Kambayashi, M.; Hashimoto, K.; Terada, Y. Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription. Endocr. J., 2010, 57, 317-24.
16. Riches, F. M.; Watts, G. F.; van Bockxmeer, F. M.; Hua, J.; Song, S.; Humphries, S. E.; Talmud, P. J. Apolipoprotein B signal peptide and apolipoprotein E genotypes as determinants of the hepatic secretion of VLDL apoB in obese men. J. Lipid. Res., 1998, 39, 1752-1758.
17. Karpe, F.; Lundahl, B.; Ehrenborg, E.; Eriksson, P.; Hamsten, A. A common functional polymorphism in the promoter region of the microsomal triglyceride transfer protein gene influences plasma LDL levels. Arterioscler. Thromb. Vasc. Biol., 1998, 18, 756-761.
18. Benhizia, F.; Reina, M.; Sturley, S.; Vilaro, S.; Ginsberg, H.; Humphries, S.; Talmud P. Variations in the human apolipoprotein B signal peptide alter apoB secretion and degradation in McArdle RH-7777 rat hepatoma cells. Atherosclerosis, 1997, 134, 65.
19. Chapman, M. J.; Le Goff, W.; Guerin, M.; Kontush, A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart. J., 2010, 31, 149-164.
20. Furuhashi, M.; Hotamisligil, G. S. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat. Rev. Drug Discov., 2008, 7, 489-503.
21. Tontonoz, P.; Spiegelman, B. M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem., 2008, 77, 289-312.
22. Strawford, A.; Antelo, F.; Christiansen, M.; Hellerstein, M. K. Adipose tissue triglyceride turnover, de novo lipogenesis, and cell proliferation in humans measured with 2H2O. Am. J. Physiol. Endocrinol. Metab., 2004, 286, E577-588.
23. Vessby, B.; Tengblad, S.; Lithell, H. Insulin sensitivity is related to the fatty acid composition of serum lipids and skeletal muscle phospholipids in 70-year-old men. Diabetologia, 1994, 37, 1044-1050.
24. Debois, D.; Bralet, M. P.; Le Naour, F.; Brunelle, A.; Laprevote, O. In situ lipidomic analysis of nonalcoholic fatty liver by cluster TOF-SIMS imaging. Anal. Chem., 2009, 81, 2823-2831.
25. Erion, D. M.; Shulman, G. I. Diacylglycerol-mediated insulin resistance. Nat. Med., 2010, 16, 400-402.
26. Fabbrini, E.; Sullivan, S.; Klein, S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology, 2010, 51, 679-689.
27. Puri, P.; Wiest, M. M.; Cheung, O.; Mirshahi, F.; Sargeant, C.; Min, H. K.; Contos, M. J.; Sterling, R. K.; Fuchs, M.; Zhou, H.; Watkins, S. M.; Sanyal, A. J. The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology, 2009, 50, 1827-1838.
28. Wolf, C.; Quinn, P. J. Lipidomics: practical aspects and applications. Prog. Lipid. Res., 2008, 47, 15-36.
29. Yang, L.; Bennett, R.; Strum, J.; Ellsworth, B. B.; Hamilton, D.; Tomlinson, M.; Wolf, R. W.; Housley, M.; Roberts, B. A.; Welsh, J.; Jackson, B. J.; Wood, S. G.; Banka, C. L.; Thulin, C. D.; Linford, M. R. Screening phosphatidylcholine biomarkers in mouse liver extracts from a hypercholesterolemia study using ESI-MS and chemometrics. Anal. Bioanal. Chem., 2009, 393, 643-654.
30. Brugger, B.; Erben, G.; Sandhoff, R.; Wieland, F. T.; Lehmann, W. D. Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry. Proc. Natl. Acad. Sci. USA, 1997, 94, 2339-2344.
31. Ivanova, P. T.; Milne, S. B.; Myers, D. S.; Brown, H. A. Lipidomics: a mass spectrometry based systems level analysis of cellular lipids. Curr. Opin. Chem. Biol., 2009, 13, 526-531.
32. Hu, C.; van der Heijden, R.; Wang, M.; van der Greef, J.; Hankemeier, T.; Xu, G., Analytical strategies in lipidomics and applications in disease biomarker discovery. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877, 2836-2846.
33. Hsu, F. F.; Bohrer, A.; Turk, J. Formation of lithiated adducts of glycerophosphocholine lipids facilitates their identification by electrospray ionization tandem mass spectrometry. J. Am. Soc. Mass Spectrom., 1998, 9, 516-526.
34. Han, X.; Yang, J.; Cheng, H.; Ye, H.; Gross, R. W. Toward fingerprinting cellular lipidomes directly from biological samples by twodimensional electrospray ionization mass spectrometry. Anal. Biochem., 2004, 330, 317-331.
35. Liebisch, G.; Binder, M.; Schifferer, R.; Langmann, T.; Schulz, B.; Schmitz, G. High throughput quantification of cholesterol and cholesteryl ester by electrospray ionization tandem mass spectrometry (ESI-MS/MS). Biochim. Biophys. Acta, 2006, 1761, 121-128.
36. Dillon, W. R. Goldstein M. Multivariate analysis, methods and application. John Wiley and Sons Chichester, UK. 1989.
37. Wiest, M. M.; Watkins, S. M. Biomarker discovery using highdimensional lipid analysis. Curr. Opin. Lipidol., 2007, 18, 181-186.
38. Vague, J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am. J. Clin. Nutr., 1956, 4, 20-34.
39. Sabir, N.; Sermez, Y.; Kazil, S.; Zencir, M. Correlation of abdominal fat accumulation and liver steatosis: importance of ultrasonographic and anthropometric measurements. Eur. J. Ultrasound, 2001, 14, 121-128.
40. Caldwell, S. H.; Patrie, J. T.; Brunt, E. M.; Redick, J. A.; Davis, C. A.; Park, S. H.; Neuschwander-Tetri, B. A. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology, 2007, 46, 1101-1107.
41. Browning, J. D.; Szczepaniak, L. S.; Dobbins, R.; Nuremberg, P.; Horton, J. D.; Cohen, J. C.; Grundy, S. M.; Hobbs, H. H. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004, 40, 1387-1395.
42. Fernandez-Real, J.M.; Vendrell, J.; Ricart, W. Circulating adiponectin and plasma fatty acid profile. Clin. Chem., 2005, 51, 603-609.